# Illumina® DRAGEN™ Secondary Analysis

Illumina DRAGEN (Dynamic Read Analysis for GENomics) secondary analysis was developed to address important challenges associated with analyzing NGS (Next Generation Sequencing) data for a range of applications, including genome, exome, transcriptome, and methylome studies. DRAGEN secondary analysis processes NGS data and enables tertiary analysis to drive insights. The available tools make up a highly accurate, comprehensive, and efficient solution that enables labs of all sizes and disciplines to do more with their genomic data.

**Product highlights**

**Accurate results:**

* Pangenome reference genome and machine learning drive unprecedented accuracy
* 99.89% accuracy score with the Precision FDA Truth Challenge V2 benchmark data (*2,3*)

**Comprehensive platform:**

* Analyze NGS data from whole genomes, exomes, methylomes, and transcriptomes
* Available on platform of choice and scalable based on needs

**Efficient analysis:**

* Process a 34x genome in \~ 30 minutes, with all supported callers with DRAGEN server v4 (*1*)
* Reduce FASTQ file sizes up to 5x with DRAGEN ORA Compression

\ <br>

*References:*

1. Illumina data on file, 2022.
2. Illumina DRAGEN Secondary Analysis is the first single platform to achieve 99.89% accuracy based on [PrecisionFDA v2 Truth Challenge Benchmark Data](https://precision.fda.gov/challenges/10). Details here [DRAGEN sets new standard for data accuracy in PrecisionFDA benchmark data](https://www.illumina.com/science/genomics-research/articles/dragen-shines-again-precisionfda-truth-challenge-v2.html). Accessed March 22, 2023
3. PrecisionFDA Truth Challenge V2: Calling Variants from Short and Long Reads in Difficult-to-Map Regions. [precision.fda.gov/challenges/10](https://precision.fda.gov/challenges/10). Accessed November 3, 2020.